AN ACT TO AMEND SECTION 41-137-5, MISSISSIPPI CODE OF 1972, TO ELIMINATE THE MANDATORY SIX-MONTH FOLLOW-UP VISIT WITH THE PRACTITIONER AFTER THE PATIENT RECEIVES THE CERTIFICATION; TO AUTHORIZE THE PRACTITIONER TO REQUEST OR REQUIRE A FOLLOW-UP EVALUATION OF THE PATIENT; TO AMEND SECTION 41-137-25, MISSISSIPPI CODE OF 1972, TO EXTEND THE VALIDITY PERIOD FOR REGISTRY IDENTIFICATION CARDS FOR RESIDENT DESIGNATED CAREGIVERS TO TWO YEARS; TO AMEND SECTION 41-137-39, MISSISSIPPI CODE OF 1972, TO REMOVE THE THC POTENCY LIMITS FOR CANNABIS TINCTURES, OILS AND CONCENTRATES; AND FOR RELATED PURPOSES.
HB 895 revises Mississippi’s medical cannabis law in three main ways. First, it removes the mandatory six-month follow-up visit after a patient receives a written certification, while still allowing the practitioner to request or require a follow-up evaluation at their discretion. Second, it extends the validity period for registry identification cards for resident designated caregivers to two years. Third, it removes the statutory THC potency cap for cannabis tinctures, oils, and concentrates, while leaving in place other potency and labeling rules for medical cannabis products.
The bill also preserves and restates a broad set of existing regulatory requirements for the medical cannabis program, including practitioner certification standards, card issuance, background checks for cannabis business personnel, security and inspection rules for establishments, purchase and possession limits, and restrictions on sales and access by minors. It continues to require in-state cultivation and limits on nonresident cardholders, and it maintains the prohibition on drive-through, curbside, or off-premises sales. The act takes effect July 1, 2026.
The overall sentiment reflected in the voting history was strongly favorable. The bill passed the House 97-11, passed the Senate 33-19 after amendment, and then the House concurred in the Senate amendments 105-3. Those margins indicate broad bipartisan support, though not unanimity, for easing some administrative burdens on patients and caregivers and for changing product potency rules.
The main points of contention appear to be the policy shift away from a mandatory follow-up visit and the removal of THC potency limits for tinctures, oils, and concentrates. Supporters likely viewed these changes as reducing unnecessary red tape and improving access for patients and caregivers, while opponents may have been concerned about reduced clinical oversight and the availability of higher-potency cannabis products. The Senate’s amendment and the narrower vote there suggest that the potency and oversight provisions were the most debated parts of the measure.
HB 895 amends Sections 41-137-5, 41-137-25, and 41-137-39 of the Mississippi Code, changing the medical cannabis framework for patient certification, caregiver card duration, and product potency regulation. It removes a mandatory follow-up appointment requirement, authorizes but does not require practitioner follow-up evaluations, extends resident designated caregiver registry cards to two years, and eliminates the THC cap for tinctures, oils, and concentrates. The bill leaves the broader medical cannabis regulatory structure intact, including licensing, background checks, security, dispensing, possession limits, and labeling requirements.
The bill’s reception was generally positive and procedurally strong, with large majorities in both chambers. The House initially passed it by a wide margin, the Senate approved an amended version by a smaller but still favorable vote, and the House then overwhelmingly concurred in the Senate amendment. This pattern suggests broad legislative agreement on the bill’s overall direction, with some reservations concentrated around the amended provisions.
The most notable disagreements centered on two policy choices: eliminating the mandatory six-month follow-up visit and removing THC potency limits for cannabis tinctures, oils, and concentrates. Critics of the follow-up change may have viewed it as reducing medical oversight, while supporters likely saw it as unnecessary bureaucracy. The potency change likely drew the sharpest scrutiny because it allows stronger concentrated products, raising concerns about safety, misuse, and product regulation. The Senate’s amendment and comparatively closer vote indicate those issues were the primary points of contention.